Prognostic Significance of the Lung Immune Prognostic Index in Patients with Resected Esophageal Squamous Cell Carcinoma

References

• Lin Y, Totsuka Y, He Y, et al. Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013;23(3):233–242. doi:10.2188/jea.JE2012016223629646
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu L, Xia W, Wang F. Anatomy of lymphatic drainage of the esophagus and lymph node metastasis of thoracic esophageal cancer. Cancer Manag Res. 2018;10:6295–6303. doi:10.2147/CMAR.S18243630568491
   PubMed Web of Science ®Google Scholar
• Feng JF, Sheng C, Zhao Q, Chen P. Prognostic value of mean platelet volume/platelet count ratio in patients with resectable esophageal squamous cell carcinoma: a retrospective study. PeerJ. 2019;7:e7246. doi:10.7717/peerj.724631328033
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2018;454(7203):436–444. doi:10.1038/nature07205
   Web of Science ®Google Scholar
• Sun Y, Zhang L. The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis. Cancer Manag Res. 2018;10:6167–6179. doi:10.2147/CMAR.S17103530538564
   PubMed Web of Science ®Google Scholar
• Wu CC, Li SH, Lu HI, et al. Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity score-matched analysis. PeerJ. 2018;6:e5655. doi:10.7717/peerj.565530258731
   PubMed Web of Science ®Google Scholar
• Chen MF, Chen PT, Kuan FC, Chen WC. The predictive value of pretreatment neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma. Ann Surg Oncol. 2019;26(1):190–199. doi:10.1245/s10434-018-6944-130362062
   PubMed Web of Science ®Google Scholar
• Ren K, Yin Y, He F, Shao Y, Wang S. Prognostic role of derived neutrophil-to-lymphocyte ratio in surgical triple-negative breast cancer. Cancer Manag Res. 2018;10:4891–4898. doi:10.2147/CMAR.S18069530425580
   PubMed Web of Science ®Google Scholar
• Gong T, Liu J, Jiang J, et al. The role of lactate deshydrogenase levels on non-small cell lung cancer prognosis: a meta-analysis. Cell Mol Biol. 2019;65(1):89–93. doi:10.14715/cmb/2019.65.1.16
   PubMed Web of Science ®Google Scholar
• Yu SL, Xu LT, Qi Q, et al. Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy. Sci Rep. 2017;7:45194. doi:10.1038/srep4519428345594
   PubMed Web of Science ®Google Scholar
• Kiba T, Ito T, Nakashima T, et al. Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival. BMC Cancer. 2014;14(1):462. doi:10.1186/1471-2407-14-46224952705
   PubMed Web of Science ®Google Scholar
• Chen R, Zhou X, Yu Z, Liu J, Huang G. Low expression of LDHB correlates with unfavorable survival in hepatocellular carcinoma: strobe-compliant article. Medicine. 2015;94(39):e1583. doi:10.1097/MD.000000000000158326426634
   PubMed Web of Science ®Google Scholar
• Schmidt H, Suciu S, Punt CJ, et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 biochemotherapy trial. J Clin Oncol. 2007;25(12):1562–1569. doi:10.1200/JCO.2006.09.027417443000
   PubMed Web of Science ®Google Scholar
• Wei XL, Zhang DS, He MM, et al. The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma. Tumour Biol. 2016;37(2):1879–1887. doi:10.1007/s13277-015-3851-y26323257
   PubMedGoogle Scholar
• Zhang P, Xi M, Li QQ, et al. The modified Glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapy. J Cancer. 2014;5(8):689–695. doi:10.7150/jca.956925258650
   PubMed Web of Science ®Google Scholar
• Huang H, Wang XP, Li XH, et al. Prognostic value of pretreatment alanine aminotransferase/aspartate aminotransferase (ALT/AST) ratio and gamma glutamyltransferase (GGT) in patients with esophageal squamous cell carcinoma. BMC Cancer. 2017;17:544. doi:10.1186/s12885-017-3523-y28806937
   PubMed Web of Science ®Google Scholar
• Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351–357. doi:10.1001/jamaoncol.2017.477129327044
   PubMed Web of Science ®Google Scholar
• Minami S, Ihara S, Komuta K. Pretreatment lung immune prognostic index is a prognostic marker of chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitor. World J Oncol. 2019;10(1):35–45. doi:10.14740/wjon117930834050
   PubMedGoogle Scholar
• Kazandjian D, Gong Y, Keegan P, Pazdur R, Blumenthal GM. Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(10):1481–1485. doi:10.1001/jamaoncol.2019.1747
   PubMed Web of Science ®Google Scholar
• Sonehara K, Tateishi K, Komatsu M, Yamamoto H, Hanaoka M. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer. Thorac Cancer. 2020;11(6):1578–1586. doi:10.1111/1759-7714.1343232286017
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Rowland A, Karapetis CS, Hopkins AM. Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials. J Thorac Oncol. 2019;14(8):1440–1446. doi:10.1016/j.jtho.2019.04.00630999110
   PubMed Web of Science ®Google Scholar
• Rice TW, Rusch VW, Ishwaran H, Blackstone EH, Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union against cancer staging manuals. Cancer. 2010;116(16):3763–3773. doi:10.1002/cncr.2514620564099
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi:10.1200/JCO.2007.12.979118323559
   PubMed Web of Science ®Google Scholar
• Su D, Zhou X, Chen Q, et al. Prognostic nomogram for thoracic esophageal squamous cell carcinoma after radical esophagectomy. PLoS One. 2015;10(4):e0124437. doi:10.1371/journal.pone.012443725893524
   PubMed Web of Science ®Google Scholar
• Zhang H, Guo XW, Yin XX, Liu YC, Ji SJ. Nomogram-integrated c-reactive protein/albumin ratio predicts efficacy and prognosis in patients with thoracic esophageal squamous cell carcinoma receiving chemoradiotherapy. Cancer Manag Res. 2019;11:9459–9468. doi:10.2147/CMAR.S22811331819611
   PubMed Web of Science ®Google Scholar
• Shao Y, Ning Z, Chen J, et al. Prognostic nomogram integrated systemic inflammation score for patients with esophageal squamous cell carcinoma undergoing radical esophagectomy. Sci Rep. 2015;5:18811. doi:10.1038/srep1881126689680
   PubMed Web of Science ®Google Scholar